Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit thein vitro growth of human head and neck cancer cells and cause rapid tumor regressionin vivo
Open Access
- 28 March 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 86 (2) , 269-275
- https://doi.org/10.1002/(sici)1097-0215(20000415)86:2<269::aid-ijc18>3.0.co;2-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosisTrends in Biotechnology, 1998
- Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient SurvivalJNCI Journal of the National Cancer Institute, 1998
- Therapeutic application of anti-growth factor receptor antibodiesCurrent Opinion in Oncology, 1998
- Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxinInternational Journal of Cancer, 1997
- Intra-tumoral application of a heregulin-exotoxin-A fusion protein causes rapid tumor regression without adverse systemic or local effectsInternational Journal of Cancer, 1997
- Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.Journal of Clinical Oncology, 1993
- Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancerCancer, 1991
- Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomasHead & Neck, 1991
- Overexpression of the c‐erbB‐2 protein in human breast tumor cell linesJournal of Cellular Biochemistry, 1989
- Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell, 1987